PCSK9 and cardiovascular disorder: Various therapies aimed at increasing the amount of LDLRs, such as statins and antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9), are effective in reducing cardiovascular disease incidence (8, 9).